The short answer
CJC-1295 is an agonist at the growth hormone-releasing hormone receptor on pituitary somatotrophs. It is based on the active GRF(1-29) fragment of native GHRH (twenty-nine residues ending in argininamide) with four substitutions that resist enzymatic degradation, chiefly by blocking the DPP-4 cleavage site at the N-terminus.
Key facts
- Receptor
- GHRH receptor (GHRHR)
- Location
- Pituitary somatotrophs
- Basis
- GRF(1-29), the active GHRH fragment
- Substitutions
- D-Ala2, Gln8, Ala15, Leu27
- Native GHRH half-life
- Minutes
- Normal signalling
- Pulsatile
What GHRH normally does
Growth hormone-releasing hormone is produced in the hypothalamus and travels through the hypophyseal portal circulation to the anterior pituitary, where it acts on somatotrophs to stimulate GH synthesis and release. Its release is pulsatile, and the resulting GH secretion is pulsatile too, a pattern that appears to matter for downstream effects.
Why only the first 29 residues
Native GHRH is 44 residues but its receptor-activating capacity resides in the N-terminal region. GRF(1-29) retains full agonist activity, which is why sermorelin (native GRF(1-29)) was developed as a therapeutic and why CJC-1295 starts from that fragment rather than the whole hormone.
Research material referenced
CJC-1295 + Ipamorelin 5+5mg, third-party HPLC tested
What each substitution addresses
D-alanine at position 2 is the critical one: DPP-4 cleaves GHRH after residue 2, and a D-amino acid is not a substrate. Gln8, Ala15 and Leu27 address further degradation-prone points. Together they take the peptide from a half-life of minutes to roughly thirty, without altering the receptor interaction.
The pulsatility question the DAC form raises
Physiological GHRH arrives in pulses. A covalently albumin-bound analogue produces continuous receptor exposure instead, which is a different stimulus. Ionescu and Frohman addressed this in 2006, reporting that pulsatile GH secretion persists during continuous stimulation. The pituitary appears to impose its own rhythm rather than simply following the input.
Why the receptor is a good target
Acting upstream at GHRH rather than administering GH directly means the pituitary retains its own regulatory feedback. That is a meaningfully different intervention from exogenous GH, and it is the general rationale for secretagogue approaches, whichever receptor they use.
Frequently asked questions
Where does CJC-1295 act?
At the GHRH receptor on pituitary somatotrophs, the same receptor native GHRH uses.
Why GRF(1-29) rather than full GHRH?
Receptor-activating capacity resides in the N-terminal region; the 29-residue fragment retains full agonist activity.
Does continuous stimulation flatten GH pulses?
Ionescu and Frohman reported pulsatile GH secretion persisting during continuous stimulation, with the pituitary imposing its own rhythm.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedIonescu M & Frohman LA. J Clin Endocrinol Metab 2006 (PMID 17018654)pubmed.ncbi.nlm.nih.gov
- PubMedTeichman SL et al. J Clin Endocrinol Metab 2006 (PMID 16352683)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · CJC-1295 (CID 91971820)pubchem.ncbi.nlm.nih.gov
- PubMedRaun et al., Ipamorelin, the first selective GH secretagogue. Eur J Endocrinol 1998 (PMID 9849822)pubmed.ncbi.nlm.nih.gov
- PubMedMüller TD et al., Ghrelin. Molecular Metabolism 2015 (PMID 26042199)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · CJC-1295 / mod GRF (1-29) (CID 56841945)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · Ipamorelin (CID 9831659)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More CJC-1295 & Ipamorelin articles
- Why These Two Are Studied TogetherTwo receptors, one output. The mechanistic rationale for pairing a GHRH analogue with a ghrelin receptor agonist - and what would be needed to test it.
- What the Published Literature ContainsTwo human pharmacokinetic studies from 2006, a 1998 selectivity paper, and comparatively little else. A small but unusually clinical evidence base.
- Storage and Reconstitution for Both CompoundsTwo peptides differing fivefold in mass, stored together but not identical. Why the DAC form's maleimide is the one genuinely reactive feature here.
- What Is CJC-1295? The Two Forms and Their MassesCJC-1295 is a GHRH analogue based on GRF(1-29) with four stabilising substitutions. Two forms exist at different masses, and they are routinely conflated.
- CJC-1295 With and Without DAC3647.2 Da against 3367.9 Da - a 279.3 Da linker separating a week-long half-life from about thirty minutes. How to tell which form you have.